Trial Profile
An Observational, Multi-Center, Cohort Study Evaluating the Antiviral Efficacy, Safety, and Tolerability in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon-alpha 2a (Pegasys)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TRACES
- 16 Aug 2016 Status changed from recruiting to completed.
- 23 Feb 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Feb 2012 New trial record